接受免疫调节剂治疗自身免疫性疾病患者的根尖周炎患病率:回顾性队列研究
这项回顾性队列研究纳入99例接受生物制剂治疗的自身免疫性疾病患者(2440颗牙)与99例无全身疾病对照(2655颗牙),比较根尖周炎患病率。结果显示自身免疫病组患病率为65.7%,显著高于对照组的46.5%(P≤.05),吸烟与根尖周炎存在显著关联。
要点
- 自身免疫病组根尖周炎患病率为65.7%,显著高于对照组的46.5%(P≤.05)。
- 吸烟与根尖周炎存在显著关联(P≤.05);女性根尖周指数低于男性(P≤.05)。
- 类风湿关节炎患者牙水平根尖周炎概率低于炎症性肠病患者(P≤.05)。
核心结论
- 接受生物制剂的自身免疫性疾病患者根尖周炎患病率更高,提示患者免疫状态可能影响根尖周炎的发生与患病率。
研究设计与样本
- 回顾性队列研究,纳入99例在大学诊所接受牙科评估的自身免疫性疾病患者(2440颗牙)及99例无全身疾病且未服药的对照(2655颗牙)。
主要发现
- 根尖周炎患病率在自身免疫病组为65.7%,在对照组为46.5%(P≤.05)。
- 吸烟与根尖周炎的关联显著(P≤.05)。
- 在自身免疫病亚组中,牙水平上类风湿关节炎患者发生根尖周炎的概率低于炎症性肠病患者(P≤.05)。
- 年龄每增加一年,根尖周炎风险增加1%;两组中女性根尖周指数均低于男性(P≤.05)。
- 与英夫利西单抗相比,托珠单抗与根尖周炎风险降低相关(P≤.05)。
关键数值与推荐
- 根尖周炎患病率:自身免疫病组65.7% vs 对照组46.5%(P≤.05)。
- 吸烟与根尖周炎关联显著(P≤.05)。
- 类风湿关节炎患者牙水平根尖周炎概率低于炎症性肠病患者(P≤.05)。
- 年龄每增加一年,根尖周炎风险增加1%。
- 女性根尖周指数低于男性(两组均P≤.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of this retrospective cohort study was to investigate the prevalence of apical periodontitis (AP) in patients affected by autoimmune diseases (ADs) taking biologic medications (BMs). METHODS: Ninety-nine patients (2440 teeth) with ADs referred to the university clinic for dental evaluation were investigated. The controls included 99 patients (2655 teeth) with no systemic diseases and taking no medications. The patients underwent a complete oral, dental, and radiographic examination for the presence of AP. The periapical index and the status of endodontic and restorative treatments were obtained. Statistics were based on descriptive analysis and continuous variables for the total sample and by subgroups. Adjusted odds ratios and 95% confidence intervals were calculated. RESULTS: The prevalence of AP was 65.7% in the autoimmune diseases group (AI) and 46.5% in the controls (P ≤ .05). The association between smoking and AP was significant (P ≤ .05). Among the AI subgroups, rheumatoid arthritis patients at the tooth level had a lower probability of developing AP than patients with inflammatory bowel disease (P ≤ .05). Furthermore, each additional year of age implied a +1% risk of AP; women had a lower periapical index than men in both groups (P ≤ .05), and tocilizumab was associated with a reduced risk of AP compared with infliximab (P ≤ .05). CONCLUSIONS: Patients with ADs taking BMs had a higher prevalence of AP. These results indicate that the status of the patients' immune system may have an effect on the development and prevalence of AP.
引用
- Ideo F, Niazi S, Mezzena S, et al. Prevalence of Apical Periodontitis in Patients with Autoimmune Diseases under Immunomodulators: A Retrospective Cohort Study. J Endod. 2022. PMID: 35257683. doi:10.1016/j.joen.2022.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。